Antifibrotic targets and therapy in HCV
- Cite this article as:
- Albanis, E. & Friedman, S.L. Curr hepatitis rep (2005) 4: 61. doi:10.1007/s11901-005-0016-2
Great progress has been made over the past 20 years in elucidating the mechanisms of hepatic fibrogenesis. The recognition of the hepatic stellate cell as the fibrogenic cell of the liver, as well as the recognition of key cytokines involved in fibrogenesis, has facilitated the development of targeted antifibrotic therapies. Patients with chronic hepatitis C and fibrosis may benefit from these novel antifibrotic therapies.